News | October 26, 2021
ANG Life Sciences India H1FY22 consolidated PAT zooms to Rs. 33.77 crore
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
